查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1449251

来那度胺市场、占有率、规模、趋势、行业分析报告：按类型、按应用、按最终用户、按剂量、按地区、按细分市场、预测，2024-2032 年

Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2个工作天内

价格

根据Polaris Market Research的最新研究，预计到2032年来那度胺的全球市场规模将达到156.7亿美元。 该报告提供了对当前市场动态的详细见解，并对未来市场成长进行了分析。

来那度胺的成长受到全球癌症患者数量不断增加的强烈影响。 该药物在治疗多发性骨髓瘤、骨髓增生异常综合症和淋巴瘤患者方面的高效性预计将推动市场需求。 製药公司使用来那度胺作为品牌名称来销售来那度胺。

製药公司为扩大来那度胺市场品牌覆盖率而采取的越来越多举措可能会刺激全球市场的成长，因为它可以提高药物的可及性。 例如，2023年3月，Natco Pharma透过其经销商Teva Pharmaceuticals宣布在美国增加2.5mg和20mg规格的Revlimid最新版本。

此外，製药公司正致力于来那度胺的市场开发，推动全球市场的扩张。 根据 Start on Therapeutics 报告 STAR-LLD，事实证明，注射到血液中的低剂量来那度胺是一些骨髓瘤患者的治疗选择。

血癌发生率的增加推动了市场对含有来那度胺的药物的需求，并增强了其深层治疗能力。 根据美国癌症协会2023年报告，美国预计将有609,820人死亡，新增1,958,310例癌症病例。 这一趋势凸显了增加来那度胺对患者的可及性的必要性。

製药公司正在透过和解解决与来那度胺生产相关的专利问题，有助于增加该药物在全球市场的供应。 例如，2023年，Sun Pharma 在与 Celgene Corporation 达成和解协议后，获得了美国 FDA 的多规格仿製药来那度胺胶囊的上市许可。 这将允许从 2026 年 1 月起在美国无限量生产，从而推动这种着名抗癌药物在预测期内的供应。

来那度胺市场报告亮点

由于其灵活性，5mg 胶囊细分市场预计将在未来几年实现最高成长。

由于来那度胺在多发性骨髓瘤治疗中的出色表现，多发性骨髓瘤细分市场占了最大的市场占有率。

由于到医院就诊的癌症患者数量不断增加，医院部门预计将占收入的更大占有率。

由于患有癌症相关併发症的患者数量不断增加，预计亚太地区将出现最快的增长。

目录

第1章简介

第 2 章执行摘要

第3章研究方法

第4章全球来那度胺市场洞察

  • 来那度胺 - 产业概况
  • 来那度胺市场动态
    • 推动者和机会
      • 多发性骨髓瘤的发生率增加
      • 加强研究来发展服用来那度胺的新方法
    • 抑制因素和挑战
      • 药物开发成本上升
  • 杵分析
  • 来那度胺产业趋势
  • 价值链分析
  • COVID-19 感染的影响分析

第5章全球来那度胺市场，依类型

  • 主要发现
  • 简介
  • 5毫克胶囊
  • 10毫克胶囊
  • 15毫克胶囊
  • 25毫克胶囊

第 6 章全球来那度胺市场，依应用划分

  • 主要发现
  • 简介
  • 多发性骨髓瘤 (MM)
  • 骨髓增生异常症候群 (MDS)
  • 淋巴瘤
  • 其他

第 7 章全球来那度胺市场，依最终用户划分

  • 主要发现
  • 简介
  • 医院
  • 癌症治疗中心
  • 调查机构

第 8 章全球来那度胺市场（按剂量）

  • 主要发现
  • 简介
  • 胶囊
  • 平板电脑

第 9 章全球来那度胺市场（依地区）

  • 主要发现
  • 简介
    • 2019-2032 年来那度胺市场评估（按地区）
  • 来那度胺市场 - 北美
    • 北美：来那度胺市场，依类型，2019-2032 年
    • 北美：来那度胺市场，依剂量，2019-2032 年
    • 北美：来那度胺市场，依应用划分，2019-2032 年
    • 北美：来那度胺市场，以最终用户划分，2019-2032 年
    • 来那度胺市场 - 美国
    • 来那度胺市场 - 加拿大
  • 来那度胺市场 - 欧洲
    • 欧洲：来那度胺市场（按类型），2019-2032 年
    • 欧洲：来那度胺市场，依剂量，2019-2032 年
    • 欧洲：来那度胺市场，依应用划分，2019-2032 年
    • 欧洲：来那度胺市场，以最终用户划分，2019-2032 年
    • 来那度胺市场 - 英国
    • 来那度胺市场 - 法国
    • 来那度胺市场 - 德国
    • Lenali Domido 市场 - 义大利
    • 来那度胺市场 - 西班牙
    • 来那度胺市场 - 荷兰
    • 来那度胺市场 - 俄罗斯
  • 来那度胺市场 - 亚太地区
    • 亚太地区：来那度胺市场，依类型，2019-2032 年
    • 亚太地区：来那度胺市场，依剂量，2019-2032 年
    • 亚太地区：来那度胺市场，依应用划分，2019-2032 年
    • 亚太地区：来那度胺市场，以最终用户划分，2019-2032 年
    • 来那度胺市场 - 中国
    • 来那度胺市场-印度
    • 来那度胺市场 - 日本
    • 来那度胺市场 - 马来西亚
    • 来那度胺市场-印度尼西亚
    • 来那度胺市场-韩国
  • 来那度胺市场 - 中东和非洲
    • 中东和非洲：来那度胺市场（按类型），2019-2032 年
    • 中东和非洲：来那度胺市场，按剂量，2019-2032 年
    • 中东和非洲：来那度胺市场，按应用划分，2019-2032 年
    • 中东和非洲：来那度胺市场，按最终用户划分，2019-2032 年
    • 来那度胺市场-沙乌地阿拉伯
    • 来那度胺市场 - 南非
    • 来那度胺市场 - 以色列
    • 来那度胺市场 - 阿拉伯联合大公国
  • 来那度胺市场 - 拉丁美洲
    • 拉丁美洲：来那度胺市场，依类型，2019-2032 年
    • 拉丁美洲：来那度胺市场，依剂量，2019-2032 年
    • 拉丁美洲：来那度胺市场，按应用划分，2019-2032 年
    • 拉丁美洲：来那度胺市场，以最终用户划分，2019-2032 年
    • 来那度胺市场 - 墨西哥
    • 来那度胺市场 - 巴西
    • 来那度胺市场-阿根廷

第10章竞争态势

  • 扩张与收购分析
    • 放大
    • 收购
  • 伙伴关係/协作/协议/揭露

第11章公司简介

  • Ablynx（Belgium）
  • Actiza（India）
  • Celgene（US）
  • Celltrion（South Korea）
  • Dexa Medical（Indonesia）
  • Exova（UK）
  • LEO Pharma（Denmark）
  • Natco Pharma（India）
  • Toyama Chemical（Japan）
Product Code: PM4437

The global lenalidomide market size is expected to reach USD 15.67 billion by 2032, according to a new study by Polaris Market Research. The report "Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of lenalidomide is highly influenced by the increasing number of cancer cases worldwide. The higher efficiency of this drug in treating multiple myeloma, myelodysplastic syndromes, and lymphoma patients is anticipated to promote its demand in the marketplace. Pharmaceutical companies use Revlimid as a brand name in the marketing of lenalidomide.

The rising initiatives by pharmaceutical companies to expand their brand coverage in the lenalidomide market are likely to stimulate the growth of the global market, as they can enhance the accessibility of medicine. For instance, in March 2023, Natco Pharma unveiled the additional strengths of Revlimid in its latest version with 2.5 mg and 20 mg strengths in the United States through its marketing agent, Teva Pharmaceuticals.

Furthermore, pharmaceutical firms are engaging in development activities related to lenalidomide, driving the expansion of the global market. According to the Start on Therapeutics report, STAR-LLD, the infusion of lower-dose lenalidomide into the blood was demonstrated to be the optimal treatment over Revlimid in some myeloma patients.

The increasing incidence of blood cancer is facilitating the need for drugs, including lenalidomide, in the marketplace, driven by its profound ability to treat the disease. According to the American Cancer Society 2023 Report, in the United States, there will be 609,820 deaths caused by cancer, and the estimated number of new cases is 1,958,310. This trend is emphasizing the need to enhance the accessibility of lenalidomide for patients.

Pharmaceutical firms are resolving patent issues associated with the production of lenalidomide with the settlements, contributing to the increased supply of this drug in the global market. For instance, in 2023, Sun Pharma received approval from the USFDA to market generic lenalidomide capsules in several strengths after entering into a settlement agreement with Celgene Corporation. With this, it can produce an unlimited quantity after January 2026 in the U.S., fueling the supply of this prominent cancer drug during the forecast period.

Lenalidomide Market Report Highlights

5mg capsules segment is anticipated to witness the highest growth in the coming years due to its flexibility.

Multiple myeloma segment accounted for the largest market share owing to the prominent performance of lenalidomide in treating multiple myeloma.

Hospitals segment is projected to experience a larger revenue share due to the rising number of cancer patients consulting hospitals.

APAC is projected to register the fastest growth attributable to the increasing number of patients with cancer-based medical complications.

The global players include Ablynx, Actiza, Celgene, Celltrion, Dexa Medical, Exova, LEO Pharma, Natco Pharma, & Toyama Chemical.

Polaris Market Research has segmented the lenalidomide market report based on type, application, end-user, dosage, and region:

Lenalidomide, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • 5mg Capsules
  • 10mg Capsules
  • 15mg Capsules
  • 25mg Capsules

Lenalidomide, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Multiple myeloma (MM)
  • Myelodysplastic syndromes (MDS)
  • Lymphoma
  • Others

Lenalidomide, End-User Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Cancer Treatment Centers
  • Research Institutes

Lenalidomide, Dosage Outlook (Revenue - USD Billion, 2019 - 2032)

  • Capsules
  • Tablets

Lenalidomide, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Lenalidomide Market Insights

  • 4.1. Lenalidomide - Industry Snapshot
  • 4.2. Lenalidomide Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. The rising incidence of multiple myeloma
      • 4.2.1.2. The increasing research studies on developing new ways of having lenalidomide
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Higher costs of drug development
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Lenalidomide Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Lenalidomide Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • 5.3. 5mg Capsules
    • 5.3.1. Global Lenalidomide Market, by 5mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.4. 10mg Capsules
    • 5.4.1. Global Lenalidomide Market, by 10mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.5. 15mg Capsules
    • 5.5.1. Global Lenalidomide Market, by 15mg Capsules, by Region, 2019-2032 (USD Billion)
  • 5.6. 25mg Capsules
    • 5.6.1. Global Lenalidomide Market, by 25mg Capsules, by Region, 2019-2032 (USD Billion)

6. Global Lenalidomide Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Multiple myeloma (MM)
    • 6.3.1. Global Lenalidomide Market, by Multiple myeloma (MM), by Region, 2019-2032 (USD Billion)
  • 6.4. Myelodysplastic syndromes (MDS)
    • 6.4.1. Global Lenalidomide Market, by Myelodysplastic syndromes (MDS), by Region, 2019-2032 (USD Billion)
  • 6.5. Lymphoma
    • 6.5.1. Global Lenalidomide Market, by Lymphoma, by Region, 2019-2032 (USD Billion)
  • 6.6. Others
    • 6.6.1. Global Lenalidomide Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Lenalidomide Market, by End-User

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 7.3. Hospitals
    • 7.3.1. Global Lenalidomide Market, by Hospitals, by Region, 2019-2032 (USD Billion)
  • 7.4. Cancer Treatment Centers
    • 7.4.1. Global Lenalidomide Market, by Cancer Treatment Centers, by Region, 2019-2032 (USD Billion)
  • 7.5. Research Institutes
    • 7.5.1. Global Lenalidomide Market, by Research Institutes, by Region, 2019-2032 (USD Billion)

8. Global Lenalidomide Market, by Dosage

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • 8.3. Capsules
    • 8.3.1. Global Lenalidomide Market, by Capsules, by Region, 2019-2032 (USD Billion)
  • 8.4. Tablets
    • 8.4.1. Global Lenalidomide Market, by Tablets, by Region, 2019-2032 (USD Billion)

9. Global Lenalidomide Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Lenalidomide Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Lenalidomide Market - North America
    • 9.3.1. North America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.3.2. North America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.3.3. North America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.3.4. North America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.3.5. Lenalidomide Market - U.S.
      • 9.3.5.1. U.S.: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.3.6. Lenalidomide Market - Canada
      • 9.3.6.1. Canada: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.4. Lenalidomide Market - Europe
    • 9.4.1. Europe: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.5. Lenalidomide Market - UK
      • 9.4.5.1. UK: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.6. Lenalidomide Market - France
      • 9.4.6.1. France: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.7. Lenalidomide Market - Germany
      • 9.4.7.1. Germany: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.8. Lenalidomide Market - Italy
      • 9.4.8.1. Italy: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.9. Lenalidomide Market - Spain
      • 9.4.9.1. Spain: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.10. Lenalidomide Market - Netherlands
      • 9.4.10.1. Netherlands: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.4.11. Lenalidomide Market - Russia
      • 9.4.11.1. Russia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.5. Lenalidomide Market - Asia Pacific
    • 9.5.1. Asia Pacific: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.5. Lenalidomide Market - China
      • 9.5.5.1. China: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.6. Lenalidomide Market - India
      • 9.5.6.1. India: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.7. Lenalidomide Market - Japan
      • 9.5.7.1. Japan: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.8. Lenalidomide Market - Malaysia
      • 9.5.8.1. Malaysia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.9. Lenalidomide Market - Indonesia
      • 9.5.9.1. Indonesia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.5.10. Lenalidomide Market - South Korea
      • 9.5.10.1. South Korea: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.6. Lenalidomide Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.5. Lenalidomide Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.6. Lenalidomide Market - South Africa
      • 9.6.6.1. South Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.7. Lenalidomide Market - Israel
      • 9.6.7.1. Israel: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.6.8. Lenalidomide Market - UAE
      • 9.6.8.1. UAE: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • 9.7. Lenalidomide Market - Latin America
    • 9.7.1. Latin America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.5. Lenalidomide Market - Mexico
      • 9.7.5.1. Mexico: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.6. Lenalidomide Market - Brazil
      • 9.7.6.1. Brazil: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
    • 9.7.7. Lenalidomide Market - Argentina
      • 9.7.7.1. Argentina: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Ablynx (Belgium)
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Actiza (India)
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Celgene (US)
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Celltrion (South Korea)
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Dexa Medical (Indonesia)
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Exova (UK)
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. LEO Pharma (Denmark)
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Natco Pharma (India)
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Toyama Chemical (Japan)
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development

List of Tables

  • Table 1 Global Lenalidomide Market, by Type, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Lenalidomide Market, by Application, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Lenalidomide Market, by End-User, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Lenalidomide Market, by Dosage, by Region, 2019-2032 (USD Billion)
  • Table 5 Lenalidomide Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 7 North America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 8 North America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 9 North America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 10 U.S.: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 11 U.S.: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 12 U.S.: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 13 U.S.: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 14 Canada: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 15 Canada: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Canada: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 17 Canada: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 18 Europe: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 19 Europe: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 20 Europe: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 21 Europe: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 22 Germany: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 23 Germany: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 24 Germany: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 25 Germany: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 26 France: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 27 France: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 28 France: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 29 France: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 30 UK: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 31 UK: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 32 UK: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 33 UK: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 34 Italy: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 35 Italy: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 36 Italy: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 37 Italy: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 42 Spain: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 43 Spain: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 44 Spain: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 45 Spain: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 46 Russia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 47 Russia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 48 Russia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 49 Russia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 54 China: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 55 China: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 56 China: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 57 China: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 58 Japan: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 59 Japan: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 60 Japan: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 61 Japan: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 62 India: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 63 India: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 64 India: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 65 India: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 74 South Korea: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 75 South Korea: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 76 South Korea: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 77 South Korea: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 78 Latin America: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 79 Latin America: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 80 Latin America: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 81 Latin America: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 82 Brazil: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 83 Brazil: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 84 Brazil: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 85 Brazil: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 86 Mexico: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 87 Mexico: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 88 Mexico: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 89 Mexico: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 90 Argentina: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 91 Argentina: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 92 Argentina: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 93 Argentina: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 98 UAE: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 99 UAE: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 100 UAE: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 101 UAE: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 106 South Africa: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 107 South Africa: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 108 South Africa: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 109 South Africa: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)
  • Table 110 Israel: Lenalidomide Market, by Type, 2019-2032 (USD Billion)
  • Table 111 Israel: Lenalidomide Market, by Application, 2019-2032 (USD Billion)
  • Table 112 Israel: Lenalidomide Market, by End-User, 2019-2032 (USD Billion)
  • Table 113 Israel: Lenalidomide Market, by Dosage, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Lenalidomide Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Dosage
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Lenalidomide Market, by Type, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Dosage
  • Figure 9. Global Lenalidomide Market, by Dosage, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Application
  • Figure 11. Global Lenalidomide Market, by Application, 2021 & 2030 (USD Billion)
  • Figure 12. Market by End-User
  • Figure 13. Global Lenalidomide Market, by End-User, 2021 & 2030 (USD Billion)